Abstract: The aim of this study was to evaluate the clinical response to a combination of intrathecal morphine and levobupivacaine in advanced cancer patients who were highly opioid-tolerant, being previously treated with multiple opioid trials unsuccessfully. Initial intrathecal morphine dose was calculated from the previous opioid consumption using a morphine oral-intrathecal ratio of 100:1. Then, doses of both drugs were modified during the treatment according to the clinical needs and balanced with adverse effects. Fifty-five patients were assessed during admission, before starting the intrathecal treatment, during the titration phase, and followed up to death, by frequent phone contacts or visits, as available. Pain and symptom intensities were recorded before starting the intrathecal treatment (T0), at time of hospital discharge (T dis), and then at 1 month (T1), 3 months (T3), 6 months (T6) intervals, and the last observation, at least 1 week before death (T death). Fifty-five patients were selected for starting an intrathecal treatment. Thirty-two patients were males. The mean age was 60 years (95% CI 57-63), and 65.4% of patients were under 65 years. The most frequent indication was the presence of adverse effects and poor pain control. Complete data with adequate follow-up until death were available in 45 patients. Statistical differences in pain intensity were found at the different time intervals examined until death. Statistical decreases in the intensity of drowsiness and confusion were found until 1 month after starting intrathecal therapy. Statistical differences were found in daily intrathecal morphine doses, with a 3-fold increase at time of hospital discharge. Subsequently, further increases in doses were not significant. Conversely, systemic opioids, expressed as oral morphine equivalents, significantly decreased at all the intervals examined until death. Early complications included mild bleeding in 2 patients, without consequences, headache in 4 patients, bladder catheterization in 6 patients, reoperation for bleeding or changes of catheter position in 4 patients, unrelated death in 1 patient, and stroke in another 1. Late complications included local infection in 2 patients, and discontinuation of intrathecal therapy due to spinal compression. In patients who had received multiple trial of opioids and routes of administration, the intrathecal treatment started with an oral-intrathecal morphine conversion ratio of 100:1, and local anesthetics at the most convenient clinical doses provided a long-term improvement of analgesia, with a decrease in adverse effects and opioid consumption until death.
I
t has been suggested that about 90% of cancer-related pain syndromes can be well controlled using the guidelines established by World Health Organization. 1 Even when the basic principles for the use of analgesic drugs are adhered to, some patients experience insufficient pain relief or considerable adverse effects from systemic opioids, and 10% of the patients with unrelieved cancer pain may still represent a significant number of patients. Opioid switching or even change of the route of opioid administration may improve the opioid response in most cases, and only a small proportion of patients with cancer pain should be candidates for spinal treatment. 2 Spinal opioids are indicated if systemic treatment has failed, either because of inadequate analgesia or because of intolerable side effects. 3 The incidence of pain requiring spinal analgesia remains unknown, as the size of the group from which patients are selected for spinal analgesia is rarely reported, and spinal opioids are often started before systemic opioid administration is optimized. The indiscriminate use of spinal opioids cannot be recommended and in some case the use is inappropriate. 4 According to the prevalent and more accepted opinion in the field of cancer pain, indications for the use of spinal opioids should include patients treated by systemic opioids with effective pain relief but with unacceptable side effects, or unsuccessful treatment with sequential strong opioid drug trials despite escalating doses. 5 However, in most studies of spinal therapy in cancer pain management, the selection of patients is often based on general considerations such as ''failure of traditional cancer pain management approaches,'' so that some patients may possibly receive spinal treatments regardless of a previous aggressive systemic approach including opioid and route switching. Thus, it is not clear at what point in the course of the treatment spinal opioids should be initiated and which patients are ideal candidates.
Another controversial point regards the dose conversion to start intrathecal morphine. Titration could be unfeasible in these situations, where patients are already receiving high doses of systemic opioids and are suffering so much that they require a rapid pain control and/or decrease of opioid-induced adverse effects intensity. Some key factors having an impact upon the selection of a starting dose in the opioid-tolerant cancer population have been explored. 6 Different oral-intrathecal ratios have been proposed, ranging from 60 to 300:1.
6-8 A very high oral-intrathecal conversion ratio could be inconvenient for a selected population with high levels of systemic opioid tolerance, resulting in further suffering for patients receiving high opioid doses. According to local policy, patients are candidates to spinal treatment only after multiple trials of opioids and routes of administration have failed. This means that this group of patients is highly resistant to systemic opioids and require a more aggressive initial conversion ratio.
The aim of this study was to evaluate the clinical response to a combination of opioids and local anesthetics spinally administered in a cohort of advanced cancer patients who were strictly selected for this indication. The second outcome was to evaluate the feasibility of starting with a morphine oral-intrathecal morphine of 100:1, and the subsequent dose changes during the treatment until death.
PATIENTS AND METHODS
A cohort of consecutive patients requiring intrathecal therapy for cancer pain was prospectively surveyed for a period of 4 years (2003 to 2006). Inclusion criteria were previous trials with at least 3 opioids (multiple switching failure) and 2 routes of administration (including the intravenous one). Opioids available were oral and intravenous morphine, transdermal fentanyl, and methadone. Institutional approval was obtained and informed consent was obtained from all the patients who had normal cognition (otherwise consent was obtained by relatives). All the procedures were carried out in the operating theater with all aseptic precautions. The patients were sedated to comfort with propofol, and placed in the lateral decubitus position. Using a standard technique, an intrathecal catheter was inserted at the most appropriate metamer, corresponding to the most painful dermatome (lumbar or thoracic). Catheter was tunneled subcutaneously to the anterior abdominal wall and connected to a port in a subcutaneous prepared pocket. A port needle, connected to a pump, was inserted. A combination of local anesthetics and morphine was started. The mixtures of morphine and levobupivacaine were as follows: at the beginning of treatment the dose were levobupivacaine 12.5 mg/d plus morphine at the starting dosage calculated from the systemic daily dose (see below), diluted in saline, to provide an infusion rate of 2 mL/h. The dose of levobupivacaine was increased to 25 mg/d before increasing the daily intrathecal morphine.
Initial intrathecal morphine dose was calculated from the previous opioid consumption using an oralintrathecal ratio of 100:1. According to a department policy, the conversion ratios used among opioids and routes of administration were the following, on the basis of known drug availability for oral, transdermal, and intravenous route of administration, and expressed as mg/d oral morphine 100 = intravenous morphine 33 = transdermal fentanyl 1 = intravenous fentanyl 1 = oral methadone 20 = intravenous methadone 16. 9 Then, doses of both drugs were modified during the treatment according to the clinical needs and balanced with adverse effects. Intrathecal adjuvants, including clonidine or ketamine, were added if necessary. Intrathecal Vancocin 50 mg was also administered. Previous systemic opioid doses were progressively tapered, after halving the doses in the first 24 hours, when possible. The combination of the treatment was gradually changed to bring pain intensity to an acceptable level (numerical scale about 4/10). After achieving an adequate analgesia, patients were discharged home and frequent phone contacts or visits, when possible, were maintained, eventually for changing pump content.
Syringe-pumps were used in hospital during dose titration of the intrathecal treatment. Once stable intrathecal doses were achieved, balloon-type devices were provided for home infusions, and changes at 5 days intervals.
Assessment
The following parameters were recorded: age, sex, primary cancer and known metastases, pain causes and mechanisms, and performance status. Patients were assessed during admission, before starting the intrathecal treatment, during the titration phase, and followed up to death, by frequent phone contacts or visits, as available. Pain and symptom intensities were recorded before starting the intrathecal treatment (T0), at time of hospital discharge (T dis), and then at 1 month (T1), 3 months (T3), 6 months (T6) intervals, and the last observation, at least 1 week before death (T death). Pain intensity was recorded by using a numerical scale from 0 to 10. Opioidrelated symptoms, including nausea and vomiting, drowsiness, confusion, constipation, dry-mouth, and so on, using a scale from 0 to 3 (not at all, slight, a lot, and awful), were recorded at the same intervals. Symptoms were assessed by the patient. Type of opioid and daily systemic opioid consumption, expressed in oral morphine equivalents, were recorded, as well symptomatic drugs. Immediate and late complications or adverse effects attributable to intrathecal treatment were recorded. Caregivers were instructed to recognize any important problems. Emerging complications were also recorded.
Statistics
Frequency analysis was performed using the Pearson w 2 test. The Paired Samples student t test procedure was used to compare the means of symptoms for a group. The Wilcoxon signed-rank test was used to compare the different nonparametric variables.
Analysis of the variance for repeated measures was used to estimate the scores or the means of symptoms at the different time intervals in the same group. All P values were 2-sided, and P values <0.05 were considered statistically significant. Data were analyzed by SPSS Release 14.0 and Systat Software 11.
RESULTS
Fifty-five patients were selected for starting an intrathecal treatment. Thirty-two patients were males. The mean age was 60 years (range: 33 to 82; 95% CI 57-63), and 65.4% of patients were under 65 years.
Opioid dosing, expressed as oral morphine equivalent before starting the intrathecal therapy was 466 mg/d (95% CI 335-597). Other characteristics of patients were described in Table 1 . Two patients were already receiving an epidural treatment unsuccessfully. Catheters were found to be dislodged and were removed before starting the intrathecal treatment.
The most frequent indication was the presence of adverse effects and poor pain control. Only 6 patients had uncontrolled pain without relevant adverse effects. Most patients had somatic pain due to bone metastases with aggravating incident pain (29 patients). Sixteen patients had mixed pain syndromes with a prevalent neuropathic pain mechanism.
Intrathecal catheter entry was mostly in the lumbar spaces, although in a certain number of patients the catheter was placed at thoracic level. Patients were discharged home 7 days after port implantation on average, and about half of patients had a survival time of more than 1 month. Clonidine was added in 1 patient. One patient did not tolerate even minimal doses of intrathecal morphine (0.5 mg/d), and continued just local anesthetics intrathecally.
In 10 patients data collection were incomplete until death due to discontinuation of the treatment for different reasons or complications. One patient, living in another province, presented meningeal symptoms 6 months after port implantation. As this patient had a von Reckinghausen disease, the catheter was removed and he preferred to continue oral methadone at high doses. Catheter was positive for Streptococcus faecalis. Two years after, he is still living and receives stable doses of methadone (range: 100 to 130 mg/d). One patient stopped the intrathecal treatment after orthopedic surgery. Others, who were living in other provinces, were lost to follow-up after their discharge home during the follow-up period, and continued the treatment under supervision of other local centers. Some other patients discontinued the intrathecal treatment due to late complications (see below).
Complete data with adequate follow-up until death were available in 45 patients. Statistical differences in pain intensity were found at the different time intervals examined until death (Table 2) . No relationship between mean admission time and age (P<0.491), sex (P<0.874), and pain intensity changes (P<0.469) was found.
Statistical decreases in the intensity of drowsiness and confusion were found until 1 month after starting intrathecal therapy. Although a decrease in intensity was observed for other opioid-related symptoms, this change did not attain a statistical significance. Statistical differences were found in daily intrathecal morphine doses, with a 3-fold increase at time of hospital discharge (from a mean of 5.76 to 14.9 mg). Subsequently, further increases in doses were not significant, doses being a mean of 19.7-mg close to death. Conversely, systemic opioid doses, expressed as oral morphine equivalents, significantly decreased at all the intervals examined until death (from a mean of 566 mg before starting intrathecal therapy to 183 mg recorded close to death). Finally, levobupivacaine doses, although increased in time, did not attain changes statistically significant. Detailed data on symptom intensity and drug doses are reported in Table 2 .
Early Complications (Occurring During Hospital Stay)
In 2 patients, mild bleeding was found during intrathecal catheter positioning, without consequences on the subsequent analgesia. Headache was reported in 4 patients. Urinary retention requiring bladder catheterization occurred in 6 patients. Numbness was never relevant and when emerging it was balanced by changing local anesthetics doses. In some patients with preexistent neurologic derangement, even low dose of local anesthetics triggered or worsened numbness. One patient was reoperated due to bleeding of subcutaneous pocket. In 3 patients intrathecal catheter entrance was changed to improve metameric analgesia. One patient died unexpectedly 3 days after starting the intrathecal treatment. Stroke was diagnosed in another patient who died during admission. In both cases, however, no relationship with the spinal treatment was found.
Late Complications
In 1 patient, catheter was removed and then replaced due to the appearance of signs of local infection. One patient stopped the intrathecal treatment due to progressive paralysis associated with the development of spinal cord compression. He developed severe drowsiness and bradypnea, probably due to relative intrathecal opioid overdosing. Intrathecal morphine was discontinued, and patient recovered in a few days. Small doses of transdermal fentanyl were sufficient to control his pain.
In 1 patient, the presence of local infection was observed, but she was not reoperated as she was considered close to death.
DISCUSSION
Several studies have reported the advantages of the intrathecal route on the epidural route, which include a better pain control, a lesser rate of late complications, lower volumes and opioid doses, [10] [11] [12] [13] [14] [15] [16] [17] [18] and the possible use of internalized pumps. 8 A synergistic effect of intrathecal morphine and local anesthetics has been shown, particularly in patients receiving previous high systemic opioid doses. 10, 17 Thus, the combination of intrathecal morphine and local anesthetics for the management of difficult pain conditions has become a standard practice at our institution since its opening.
Many studies have shown favorable outcomes with spinal treatment. However, details on the previous systemic treatment and optimization of opioid therapy, and other data are lacking. Thus, it is difficult to judge the real need and efficacy of a spinal treatment in patients really unresponsive to systemic opioids and whether the outcomes obtained are based on an unselected population not adequately treated. In a comparative study, an implantable drug delivery system for intrathecal morphine provided a better impact on pain, opioid-related adverse effects, and survival, compared with comprehensive medical management. 8 Several criticisms, principally regarding patients' selection and definition of standard care, have been reported. Moreover, local anesthetics, probably given at low doses due the limitation of the internal pump volumes, were added in some cases, and also a small number of patients taking nonopioids only were included. The present study demonstrated that intrathecal treatment is really effective even in a very selected population, that is patients who had received aggressive systemic treatments, including at least 3 trials with different opioids, and 2 routes of administration, including intravenous morphine, and not only in patients generically considered unresponsive or receiving a certain dose of systemic opioids. 8 Doses used in this study also confirm the complexity of the pain syndromes, reaching a mean of about 20 and 54 mg/d of intrathecal morphine and levobupivacaine, respectively, in a mean survival time of 71 days, with a relatively minimal opioid escalation index of 0.19 mg/d. In a previous experience at home using lower starting intrathecal opioid doses, the escalation index was 0.4 mg/d, 19 which indicates that the initial starting doses do not influence the subsequent intrathecal morphine dose escalation. The average dose escalated quickly during titration and then stabilized, as described in other studies of cancer patients in comparison with a more gradual, linear increase in dose observed in noncancer patients. 20 As expected, intrathecal doses of morphine were relatively high, but similar with those reported in a similar group of highly opioid-tolerant patients with pancreatic cancer. 21 Of interest, 9 patients required more than 30 mg/d, and 4 of them 50 mg/d of intrathecal morphine. Very high doses of intrathecal morphine (140 mg/d) have been occasionally reported. 22 Doses of levobupivacaine remained relatively stable and increased, but not statistically, close to death, possibly due to the development of tachyphylaxis.
Neuroexcitatory effects observed with high doses of opioids are of concern. 23 In this study this was not apparently observed, possibly due to the concomitant use of local anesthetics, which may have some protective effects, 24 although this remains just a mere speculation. Intrathecal doses up to 73 mg/d were not associated with sedation or adverse effects which prevented achievement of pain control. 7 The incidence of adverse effects of intrathecal morphine does not seem to be associated with its doses. 25 It seems that impaired rostral diffusion is determinant for inducing spinal cord excitation resulting in myoclonus, 26 rather than the dose itself. Another controversial point is the starting dose of intrathecal morphine. Long-term dose titration could be detrimental for patients, increasing their suffering and reducing their compliance. Doses should be adjusted by age, injection site, and patient's medical condition, and degree of tolerance to opioids. 27 Some key factors having an impact upon the selection of a starting dose in the opioid-tolerant cancer population have been described. 6 An oral-intrathecal ratio of 200 to 300:1 has been suggested, and some predictive factors, including previous opioid dose have been recommended. 5, 8 It is well known that some cross tolerance exists between spinal and systemic routes, although some levels of asymmetric tolerance may occur, 28 and could be used to take some advantages in terms of opioid dosing. Patients who have been intensively treated with several opioids, administered by different routes, are challenging, and dose titration starting with minimal doses of intrathecal morphine may be time loosing in a population who is, per definition, really suffering. A more aggressive ratio, 100:1, used in this trial was effective and did not result in relevant opioid-related complications. The choice of such starting doses of intrathecal morphine were based on local policy and previous experience in patients highly tolerant to systemic opioids. Other researchers have been using even important conversion ratios of 60:1. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] In fact, the parameters to candidate patients to the intrathecal treatment were different attempts with opioids and routes, including the use of intravenous route, retained to be able to improve the opioid response in some difficult situations. 29 Of interest, it should be outlined that even so, a further dose titration was required, and doses at discharge, that is in a phase of stabilization when analgesia and adverse effects were considered acceptable, were 3 times as higher as the starting doses (about an oral-final intrathecal morphine ratio of 33:1). This observation suggests that the risk of overmedication is unlikely in such kind of patients, also considering that local anesthetics at optimized doses were added to improve analgesia. Using opioids alone probably would have required even higher starting doses or a prolonged doses titration. Therefore, patients selected after stringent criteria may reduce time of dose titration to achieve adequate analgesia by using a more incisive oral-intrathecal morphine conversion ratio. Most patients could stop systemic opioids or decreasing their doses until death. This resulted in a clear improvement of adverse effects, particularly drowsiness, after starting the intrathecal treatment. Deterioration of the clinical condition could be responsible of some adverse effects, commonly attributed to opioids, particularly in last weeks of life, when it is difficult to distinguish between opioid-related effects and disease progression-related symptoms.
In an algorithm resulting from a consensus conference, intrathecal dugs were arranged in a hierarchy according to evidence of safety, efficacy, and experience. A combination of morphine and local anesthetics was placed as second step. 30 Although these guidelines are probably appropriate for noncancer pain, clinical sense suggests that cancer patients highly tolerant to systemic opioids require an intensive polyanalgesic intervention to improve analgesia. [13] [14] [15] [16] [17] Early and late complication rates, either technical or pharmacologic, were similar to those reported in previous studies, 2, 12 and managed accordingly. Urinary retention occurred in 6 patients and was specifically attributed to the intrathecal treatment. Similarly, numbness was difficult to assess, particularly with phone contacts. For both problems a preexisting neurologic damage cannot be excluded. Moreover, the entity of these problems was difficult to distinguish due to the general derangement of the clinical conditions in the long-term period. Spinal compression may produce neurologic impairment during long-term intrathecal treatment. 31 In 1 patient who developed spinal cord compression, the intrathecal therapy was discontinued, and transdermal fentanyl was found to be effective in relieving pain. It can be hypothesized that the cord compression relieves pain by interrupting the nociceptive pathway, and consequently the current intrathecal morphine dose was relatively overdosed as the neurologic damage was completed and the pain had been relieved. 32 Evidence exists that the formation of granulomatous masses are related to the use of higher doses at high concentration. 33, 34 Although no suspicion for the development of intrathecal granulomas raised by patients' assessment and clinical course, this doubt could not be resolved, as autoptic data were not available.
This study first, provided further information on the outcome of an intrathecal treatment in highly opioid tolerant patients. Given the complexity of this kind of patients and the need to provide individually the best outcome, controlled studies are really difficult to perform and often provide information, which may be inferred by protocol limitation, not always ethically acceptable.
In conclusion, in patients who had received multiple trial of opioids and routes of administration, the intrathecal treatment started with an oral-intrathecal morphine conversion ratio of 100:1, and local anesthetics at the most convenient clinical doses, provided a rapid and long-term improvement of analgesia, with a decrease in adverse effects and opioid consumption until death.
